

CLAIMS

What is claimed is:

1. A compound of formula (I),

(R²R³)-A⁷-A⁸-A⁹-A¹⁰-A¹¹-A¹²-A¹³-A¹⁴-A¹⁵-A¹⁶-A¹⁷-A¹⁸-A¹⁹-A²⁰-A²¹-A²²-A²³-A²⁴-A²⁵-A²⁶-A²⁷-A²⁸-A²⁹-A³⁰-A³¹-A³²-A³³-A³⁴-A³⁵-A³⁶-A³⁷-A³⁸-A³⁹-R¹ (SEQ ID NO:412),

(I)

wherein

10 A⁷ is L-His, Ura, Paa, Pta, Amp, Tma-His, des-amino-His, or deleted;

A⁸ is Ala, D-Ala, Aib, Acc, N-Me-Ala, N-Me-D-Ala or N-Me-Gly;

A⁹ is Glu, N-Me-Glu, N-Me-Asp or Asp;

A¹⁰ is Gly, Acc, β-Ala or Aib;

A¹¹ is Thr or Ser;

15 A¹² is Phe, Acc, Aic, Aib, 3-Pal, 4-Pal, β -Nal, Cha, Trp or X¹-Phe;

A¹³ is Thr or Ser;

A¹⁴ is Ser or Aib:

A¹⁵ is Asp or Glu;

A¹⁶ is Val, Acc, Aib, Leu, Ile, Tle, Nle, Abu, Ala or Cha;

20 A¹⁷ is Ser or Thr;

A¹⁸ is Ser or Thr;

A¹⁹ is Tyr, Cha, Phe, 3-Pal, 4-Pal, Acc, β-Nal or X¹-Phe;

A²⁰ is Leu, Acc, Aib, Nle, Ile, Cha, Tle, Val, Phe or X¹-Phe;

A²¹ is Glu or Asp;

25 A²² is Gly, Acc, β -Ala, Glu or Aib;

A²³ is Gln, Asp, Asn or Glu;

A^{24} is Ala, Aib, Val, Abu, Tle or Acc;

A²⁵ is Ala, Aib, Val, Abu, Tle, Acc, Lys, Arg, hArg, Orn, HN-CH((CH₂)_n-N(R¹⁰-R¹¹))-C(O) or NH-CH((CH₂)_e-X³)-C(O);

30 A²⁶ is Lys, Arg, hArg, Orn, HN-CH((CH₂)_n-N(R¹⁰-R¹¹))-C(O) or NH-CH((CH₂)_e-X³)-C(O);

A²⁷ is Glu Asp, Leu, Aib or Lys;

A²⁸ is Phe, Pal, β-Nal, X¹-Phe, Aic, Acc, Aib, Cha or Trp;

A²⁹ is Ile, Acc, Aib, Leu, Nle, Cha, Tle, Val, Abu, Ala or Phe;

A³⁰ is Ala, Aib or Acc;

A³¹ is Trp, β-Nal, 3-Pal, 4-Pal, Phe, Acc, Aib or Cha;

5 A³² is Leu, Acc, Aib, Nle, Ile, Cha, Tle, Phe, X¹-Phe or Ala;

A³³ is Val, Acc, Aib, Leu, Ile, Tle, Nle, Cha, Ala, Phe, Abu, Lys or X¹-Phe;

A³⁴ is Lys, Arg, hArg, Orn, HN-CH((CH₂)_n-N(R¹⁰-R¹¹))-C(O) or NH-CH((CH₂)_e-X³)-C(O);

A³⁵ is Gly, β-Ala, D-Ala, Gaba, Ava, NH-(CH₂)_m-C(O), Aib, Acc or a D-amino acid;

A³⁶ is L-or D-Arg, D-or L-Lys, D-or L-hArg, D-or L-Orn, HN-CH((CH₂)_n-N(R¹⁰-R¹¹))-C(O),

10 NH-CH((CH₂)_e-X³)-C(O) or deleted;

A³⁷ is Gly, β-Ala, Gaba, Ava, Aib, Acc, Ado, Arg, Asp, Aun, Aec, NH-(CH₂)_m-C(O), HN-CH((CH₂)_n-N(R¹⁰-R¹¹))-C(O), a D-amino acid, or deleted;


A³⁸ is D-or L-Lys, D-or L-Arg, D-or L-hArg, D-or L-Orn, HN-CH((CH₂)_n-N(R¹⁰-R¹¹))-C(O), NH-CH((CH₂)_e-X³)-C(O), Ava, Ado, Aec or deleted;

15 A³⁹ is D-or L-Lys, D-or L-Arg, HN-CH((CH₂)_n-N(R¹⁰-R¹¹))-C(O), Ava, Ado, or Aec;


X¹ for each occurrence is independently selected from the group consisting of (C₁-C₆)alkyl, OH and halo;

R¹ is OH, NH₂, (C₁-C₃₀) alkoxy, or NH-X²-CH₂-Z⁰, wherein X² is a (C₁-C₁₂) hydrocarbon moiety, and Z⁰ is H, OH, CO₂H or CONH₂;

20



X³ is




25

or -C(O)-NHR¹², wherein X⁴ is, independently for each occurrence, -C(O)-, -NH-C(O)- or -CH₂-, and wherein f is, independently for each occurrence, an integer from 1 to 29 inclusive;

each of R² and R³ is independently selected from the group consisting of H, (C₁-C₃₀)alkyl, (C₂-C₃₀)alkenyl, phenyl(C₁-C₃₀)alkyl, naphthyl(C₁-C₃₀)alkyl, hydroxy(C₁-C₃₀)alkyl, hydroxy(C₂-C₃₀)alkenyl, hydroxyphenyl(C₁-C₃₀)alkyl, and hydroxynaphthyl(C₁-C₃₀)alkyl; or one of R² and

30

R³ is (CH₃)₂-N-C=N(CH₃)₂, (C₁-C₃₀)acyl, (C₁-C₃₀)alkylsulfonyl, C(O)X⁵,



; wherein Y is H, OH or NH₂; r is 0 to 4; q is 0 to 4; and X⁵ is (C₁-C₃₀)alkyl, (C₂-C₃₀)alkenyl, phenyl(C₁-C₃₀)alkyl, naphthyl(C₁-C₃₀)alkyl, hydroxy(C₁-C₃₀)alkyl, hydroxy(C₂-C₃₀)alkenyl,

5 hydroxyphenyl(C₁-C₃₀)alkyl or hydroxynaphthyl(C₁-C₃₀)alkyl;


e is, independently for each occurrence, an integer from 1 to 4 inclusive;

m is, independently for each occurrence, an integer from 5 to 24 inclusive;

n is, independently for each occurrence, an integer from 1 to 5, inclusive;

each of R¹⁰ and R¹¹ is, independently for each occurrence, H, (C₁-C₃₀)alkyl, (C₁-C₃₀)acyl, (C₁-

10 C₃₀)alkylsulfonyl, -C((NH)(NH₂)) or




R¹² and R¹³ each is, independently for each occurrence, (C₁-C₃₀)alkyl;

15 provided that:

when A⁷ is Ura, Paa or Pta, then R² and R³ are deleted;

when R¹⁰ is (C₁-C₃₀)acyl, (C₁-C₃₀)alkylsulfonyl, -C((NH)(NH₂)) or



(i) at least one amino acid of a compound of formula (I) is not the same as the native sequence of hGLP-1(7-36, -37 or -38)NH₂ or hGLP-1(7-36, -37 or -38)OH;

(ii) a compound of formula (I) is not an analogue of hGLP-1(7-36, -37 or -38)NH₂ or hGLP-1(7-36, -37 or -38)OH wherein a single position has been substituted by Ala;

(iii) a compound of formula (I) is not (Arg^{26,34}, Lys³⁸)hGLP-1(7-38)-E, (Lys²⁶(N_ε-alkanoyl))hGLP-1(7-36, -37 or -38)-E, (Lys³⁴(N_ε-alkanoyl))hGLP-1(7-36, -37 or -38)-E, (Lys^{26,34}-bis(N_ε-alkanoyl))hGLP-1(7-36, -37 or -38)-E, (Arg²⁶, Lys³⁴(N_ε-alkanoyl))hGLP-1(8-36, -37 or -38)-E, (Arg^{26,34}, Lys³⁶(N_ε-alkanoyl))hGLP-1(7-36, -37 or -38)-E or (Arg^{26,34}, Lys³⁸(N_ε-alkanoyl))hGLP-1(7-38)-E, wherein E is -OH or -NH₂;

(iv) a compound of formula (I) is not Z¹-hGLP-1(7-36, -37 or -38)-OH, Z¹-hGLP-1(7-36, -37 or

-38)-NH₂, wherein Z¹ is selected from the group consisting of:

(e) (Arg²⁶), (Arg³⁴), (Arg^{26,34}), (Lys³⁶), (Arg²⁶, Lys³⁶), (Arg³⁴, Lys³⁶), (D-Lys³⁶), (Arg³⁶), (D-Arg³⁶), (Arg^{26,34}, Lys³⁶) or (Arg^{26,36}, Lys³⁴);

(f) (Asp²¹);

5 (g) at least one of (Aib⁸), (D-Ala⁸) and (Asp⁹); and

(h) (Tyr⁷), (N-acyl-His⁷), (N-alkyl-His⁷), (N-acyl-D-His⁷) or (N-alkyl-D-His⁷);

(v) a compound of formula (I) is not a combination of any two of the substitutions listed in groups (a) to (d); and

10 (vi) a compound of formula (I) is not (N-Me-Ala⁸)hGLP-1(8-36 or -37), (Glu¹⁵)hGLP-1(7-36 or -37), (Asp²¹)hGLP-1(7-36 or -37) or (Phe³¹)hGLP-1(7-36 or -37) or a pharmaceutically acceptable salt thereof.


15 2. A compound according to claim 1, wherein A¹¹ is Thr; A¹³ is Thr; A¹⁵ is Asp; A¹⁷ is Ser; A¹⁸ is Ser; A²¹ is Glu; A²³ is Gln or Glu; A²⁷ is Glu; A³¹ is Trp; or a pharmaceutically acceptable salt thereof.

20 3. A compound according to claim 2, wherein A⁹ is Glu, N-Me-Glu or N-Me-Asp; A¹² is Phe, Acc or Aic; A¹⁶ is Val, Acc or Aib; A¹⁹ is Tyr; A²⁰ is Leu, Acc or Cha; A²⁴ is Ala, Aib or Acc; A²⁵ is Ala, Aib, Acc, Lys, Arg, hArg, Orn, HN-CH((CH₂)_n-N(R¹⁰R¹¹))-C(O) or HN-CH((CH₂)_e-X³)-C(O); A²⁸ is Phe; A²⁹ is Ile or Acc; A³⁰ is Ala or Aib; A³² is Leu, Acc or Cha; and A³³ is Val or Acc; or a pharmaceutically acceptable salt thereof.


25 4. A compound according to claim 3, wherein A⁸ is Ala, D-Ala, Aib, A6c, A5c, N-Me-Ala, N-Me-D-Ala or N-Me-Gly; A¹⁰ is Gly; A¹² is Phe, A6c or A5c; A¹⁶ is Val, A6c or A5c; A²⁰ is Leu, A6c, A5c or Cha; A²² is Gly, β-Ala or Aib; A²⁴ is Ala or Aib; A²⁹ is Ile, A6c or A5c; A³² is Leu, A6c, A5c or Cha; A³³ is Val, A6c or A5c; A³⁵ is Aib, β-Ala, Ado, A6c, A5c or Gly; and A³⁷ is Gly, Aib, β-Ala, Ado, D-Ala or deleted; or a pharmaceutically acceptable salt thereof.

30 5. A compound according to claim 4 or a pharmaceutically acceptable salt thereof, wherein X⁴ for each occurrence is -C(O)-; e for each occurrence is independently 1 or 2; and R¹ is OH or NH₂.


6. A compound according to claim 5 or a pharmaceutically acceptable salt thereof, wherein R^2 is H and R^3 is (C_1-C_{30}) alkyl, (C_2-C_{30}) alkenyl, (C_1-C_{30}) acyl, (C_1-C_{30}) alkylsulfonyl.




or



7. A compound according to claim 5 or a pharmaceutically acceptable salt thereof, wherein R^{10} is (C_1-C_{30}) acyl, (C_1-C_{30}) alkylsulfonyl or



8. A compound according to claim 7 or a pharmaceutically acceptable salt thereof, wherein R^{10} is (C_4-C_{20}) acyl, (C_4-C_{20}) alkylsulfonyl or



9. (Amended) A compound according to claim 1 wherein said compound is
 $(\text{Aib}^{8,35})\text{hGLP-1(7-36)NH}_2$ (SEQ ID NO:2),
 $((\text{N}^{\alpha}\text{-HEPES-His})^7, \text{Aib}^{8,35})\text{hGLP-1(7-36)NH}_2$ (SEQ ID NO:3),
 $((\text{N}^{\alpha}\text{-HEPA-His})^7, \text{Aib}^{8,35})\text{hGLP-1(7-36)NH}_2$ (SEQ ID NO:4),
 $(\text{Aib}^8, \beta\text{-Ala}^{35})\text{hGLP-1(7-36)NH}_2$ (SEQ ID NO:5),
 $(\text{Aib}^{8,35}, \text{Arg}^{26,34}, \text{Lys}^{36}(\text{N}_{\epsilon}\text{-tetradecanoyl}))\text{hGLP-1(7-36)NH}_2$ (SEQ ID NO:6),
 $(\text{Aib}^{8,35}, \text{Arg}^{26}, \text{Lys}^{34}(\text{N}_{\epsilon}\text{-tetradecanoyl}))\text{hGLP-1(7-36)NH}_2$ (SEQ ID NO:7),

(Aib^{8,35,37}, Arg^{26,34}, Lys³⁸(N_ε-tetradecanoyl))hGLP-1(7-38)NH₂ (SEQ ID NO:8),
 (Aib^{8,35}, Arg^{26,34}, Lys³⁶(N_ε-decanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:9),
 (Aib^{8,35}, Arg^{26,34}, Lys³⁶(N_ε-dodecanesulfonyl))hGLP-1(7-36)NH₂ (SEQ ID NO:10),
 (Aib^{8,35}, Arg^{26,34}, Lys³⁶(N_ε-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID
 5 NO:11),
 (Aib^{8,35}, Arg^{26,34}, Asp³⁶(1-(4-tetradecyl-piperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:12),
 (Aib^{8,35}, Arg^{26,34}, Asp³⁶(1-tetradecylamino))hGLP-1(7-36)NH₂ (SEQ ID NO:13),
 (Aib^{8,35}, Arg^{26,34}, Lys³⁶(N_ε-tetradecanoyl), β-Ala³⁷)hGLP-1(7-37)-OH (SEQ ID NO:14) or
 (Aib^{8,35}, Arg^{26,34}, Lys³⁶(N_ε-tetradecanoyl))hGLP-1(7-36)-OH (SEQ ID NO:15), or a
 10 pharmaceutically acceptable salt thereof.

10. (Amended) A compound according to claim 9 wherein said compound is
 (Aib^{8,35})hGLP-1(7-36)NH₂ (SEQ ID NO:2),
 (Aib⁸, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:5),
 15 (Aib^{8,35}, Arg²⁶, Lys³⁴(N_ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:7),
 (Aib^{8,35,37}, Arg^{26,34}, Lys³⁸(N_ε-tetradecanoyl))hGLP-1(7-38)NH₂ (SEQ ID NO:8),
 (Aib^{8,35}, Arg^{26,34}, Lys³⁶(N_ε-decanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:9), or
 (Aib^{8,35}, Arg^{26,34}, Lys³⁶(N_ε-tetradecanoyl), β-Ala³⁷)hGLP-1(7-37)-OH (SEQ ID NO:14), or a
 pharmaceutically acceptable salt thereof.

20 11. A pharmaceutical composition comprising an effective amount of a compound
 according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically
 acceptable carrier or diluent.

25 12. A method of eliciting an agonist effect from a GLP-1 receptor in a subject in need
 thereof which comprises administering to said subject an effective amount of a compound
 according to claim 1 or a pharmaceutically acceptable salt thereof.

30 13. A method for treating a disease selected from the group consisting of Type I diabetes,
 Type II diabetes, obesity, glucagonomas, secretory disorders of the airway, metabolic disorder,
 arthritis, osteoporosis, central nervous system disease, restenosis and neurodegenerative disease,

in a subject in need thereof which comprises administering to said subject an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

14. A method according to claim 13 wherein said disease is Type I diabetes or Type II diabetes.

15. (Amended) A compound according to claim 1 wherein said compound is

(Aib³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:71);

(β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:72);

10 ((N^α-Me-His)⁷, Aib^{8,35})hGLP-1(7-36)NH₂ (SEQ ID NO:73);

((N^α-Me-His)⁷, Aib⁸, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:74);

((N^α-Me-His)⁷, Aib^{8,35}, Arg^{26,34})hGLP-1(7-36)NH₂ (SEQ ID NO:75);

((N^α-Me-His)⁷, Aib⁸, Arg^{26,34}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:76);

(Aib⁸, A6c³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:77);

15 (Aib⁸, A5c³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:78);

(Aib⁸, D-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:79);

(Aib^{8,35}, A6c³²)hGLP-1(7-36)NH₂ (SEQ ID NO:16);

(Aib^{8,35}, A5c³²)hGLP-1(7-36)NH₂ (SEQ ID NO:80);

(Aib^{8,35}, Glu²³)hGLP-1(7-36)NH₂ (SEQ ID NO:17);

20 (Aib^{8,24,35})hGLP-1(7-36)NH₂ (SEQ ID NO:18);

(Aib^{8,30,35})hGLP-1(7-36)NH₂ (SEQ ID NO:81);

(Aib^{8,25,35})hGLP-1(7-36)NH₂ (SEQ ID NO:82);

(Aib^{8,35}, A6c^{16,20})hGLP-1(7-36)NH₂ (SEQ ID NO:83);

(Aib^{8,35}, A6c^{16,29,32})hGLP-1(7-36)NH₂ (SEQ ID NO:84);

25 (Aib^{8,35}, A6c^{20,32})hGLP-1(7-36)NH₂ (SEQ ID NO:85);

(Aib^{8,35}, A6c²⁰)hGLP-1(7-36)NH₂ (SEQ ID NO:86);

(Aib^{8,35}, Lys²⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:87);

(Aib^{8,24,35}, A6c²⁰)hGLP-1(7-36)NH₂ (SEQ ID NO:88);

(Aib^{8,35}, A6c^{29,32})hGLP-1(7-36)NH₂ (SEQ ID NO:89);

30 (Aib^{8,24,35}, A6c^{29,32})hGLP-1(7-36)NH₂ (SEQ ID NO:90);

(Aib^{8,35}, A6c¹²)hGLP-1(7-36)NH₂ (SEQ ID NO:91);

- (Aib^{8,35}, Cha²⁰)hGLP-1(7-36)NH₂ (SEQ ID NO:92);
 (Aib^{8,35}, A6c³³)hGLP-1(7-36)NH₂ (SEQ ID NO:93);
 (Aib^{8,35}, A6c^{20,32})hGLP-1(7-36)NH₂ (SEQ ID NO:85);
 (Aib⁸, A6c^{16,20}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:94);
 5 (Aib^{8,35}, β-Ala²²)hGLP-1(7-36)NH₂ (SEQ ID NO:95);
 (Aib^{8,22,35})hGLP-1(7-36)NH₂ (SEQ ID NO:96);
 (Aib^{8,35}, Glu²³, A6c³²)hGLP-1(7-36)NH₂ (SEQ ID NO:19);
 (Aib^{8,24,35}, Glu²³, A6c³²)hGLP-1(7-36)NH₂ (SEQ ID NO:97);
 (Aib^{8,24,25,35}, Glu²³, A6c³²)hGLP-1(7-36)NH₂ (SEQ ID NO:98);
 10 (Aib^{8,24,25,35}, A6c^{16,20,32}, Glu²³)hGLP-1(7-36)NH₂ (SEQ ID NO:99);
 (Aib⁸, A6c³², β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:100);
 (Aib⁸, A5c³², β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:101);
 (Aib⁸, Glu²³, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:20);
 (Aib^{8,24}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:102);
 15 53: (Aib^{8,30}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:103);
 (Aib^{8,25}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:104);
 (Aib⁸, A6c^{16,20}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:94);
 (Aib⁸, A6c^{16,29,32}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:105);
 (Aib⁸, A6c^{20,32}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:106);
 20 (Aib⁸, A6c²⁰, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:107);
 (Aib⁸, Lys²⁵, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:108);
 (Aib^{8,24}, A6c²⁰, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:109);
 (Aib⁸, A6c^{29,32}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:110);
 (Aib^{8,24}, A6c^{29,32}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:111);
 25 (Aib⁸, A6c¹², β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:112);
 (Aib⁸, Cha²⁰, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:113);
 (Aib⁸, A6c³³, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:114);
 (Aib⁸, A6c^{20,32}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:106);
 (Aib⁸, β-Ala^{22,35})hGLP-1(7-36)NH₂ (SEQ ID NO:115);
 30 (Aib^{8,22}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:116);
 (Aib⁸, Glu²³, A6c³², β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:117);

- (Aib^{8,24}, Glu²³, A6c³², β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:118);
 (Aib^{8,24}, Glu²³, A6c³², Lys³⁴(N^ε-octanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:119);
 (Aib^{8,24,25}, Glu²³, A6c³², β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:120);
 (Aib^{8,24,25}, A6c^{16,20,32}, Glu²³, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:121);
 5 (Aib^{8,35}, D-Arg³⁶)hGLP-1(7-36)NH₂ (SEQ ID NO:122);
 (Aib^{8,35}, D-Lys³⁶)hGLP-1(7-36)NH₂ (SEQ ID NO:123);
 (Aib⁸, β-Ala³⁵, D-Arg³⁶)hGLP-1(7-36)NH₂ (SEQ ID NO:124);
 (Aib⁸, β-Ala³⁵, D-Lys³⁶)hGLP-1(7-36)NH₂ (SEQ ID NO:125);
 (Aib^{8,35}, Arg^{26,34})hGLP-1(7-36)NH₂ (SEQ ID NO:21);
 10 (Aib⁸, Arg^{26,34}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:126);
 (Aib^{8,35}, Arg^{25,26,34})hGLP-1(7-36)NH₂ (SEQ ID NO:127);
 (Aib⁸, Arg^{25,26,34}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:128);
 (Aib⁸, Arg^{26,34}, β-Ala³⁵, Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)OH (SEQ ID NO:129);
 (Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-37)OH (SEQ ID NO:130);
 15 (Aib^{8,35,37}, Arg^{26,34}, Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-37)OH (SEQ ID NO:131);
 (Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^ε-tetradecanoyl), D-Ala³⁷)hGLP-1(7-37)OH (SEQ ID NO:132);
 (Aib^{8,35,37}, Arg^{26,34}, Lys³⁸(N^ε-tetradecanoyl))hGLP-1(7-38)OH (SEQ ID NO:133);
 (Aib^{8,35}, Arg^{26,34}, β-Ala³⁷, Lys³⁸(N^ε-tetradecanoyl))hGLP-1(7-38)OH (SEQ ID NO:134);
 (Aib^{8,35}, Arg^{26,34}, Lys³⁸(N^ε-tetradecanoyl))hGLP-1(7-38)OH (SEQ ID NO:135);
 20 (Aib⁸, Arg^{26,34}, Lys³⁶(N^ε-tetradecanoyl), β-Ala³⁷)hGLP-1(7-37)OH (SEQ ID NO:136);
 (Aib^{8,37}, Arg^{26,34}, Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-37)OH (SEQ ID NO:137);
 (Aib^{8,35}, Arg^{26,34}, Ado³⁷)hGLP-1(7-37)OH (SEQ ID NO:138);
 (Aib^{8,35}, Arg^{26,34}, Ado³⁷)hGLP-1(7-37)NH₂ (SEQ ID NO:139);
 (Aib⁸, Arg^{26,34}, Lys³⁶(N^ε-tetradecanoyl), D-Ala³⁷)hGLP-1(7-37)OH (SEQ ID NO 140);
 25 (Aib^{8,37}, Arg^{26,34}, Lys³⁸(N^ε-tetradecanoyl))hGLP-1(7-38)OH (SEQ ID NO:141);
 (Aib⁸, Arg^{26,34}, β-Ala³⁷, Lys³⁸(N^ε-tetradecanoyl))hGLP-1(7-38)OH (SEQ ID NO:142);
 (Aib^{8,35}, Lys²⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:143);
 (Aib^{8,35}, Lys²⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:144);
 (Aib^{8,35}, Lys²⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:145);
 30 (Aib⁸, Lys²⁶(N^ε-octanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:146);
 (Aib⁸, Lys²⁶(N^ε-tetradecanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:147);

- (Aib⁸, Lys²⁶(N^ε-hexadecanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:148);
 (Aib^{8,35}, Lys²⁶(N^ε-octanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:149);
 (Aib^{8,35}, Lys²⁶(N^ε-tetradecanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:150);
 (Aib^{8,35}, Lys²⁶(N^ε-hexadecanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:151);
 5 (Aib^{8,35}, Lys²⁶(N^ε-decanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:152);
 (Aib^{8,35}, Lys²⁵, Lys²⁶(N^ε-octanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:153);
 (Aib^{8,35}, Lys²⁵, Lys²⁶(N^ε-tetradecanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:154);
 (Aib^{8,35}, Lys²⁵, Lys²⁶(N^ε-hexadecanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:155);
 (Aib^{8,35}, Arg^{25,34}, Lys²⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:156);
 10 (Aib^{8,35}, Arg^{25,34}, Lys²⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:157);
 (Aib^{8,35}, Arg^{25,34}, Lys²⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:158);
 (Aib^{8,35}, Arg^{25,34}, Lys²⁶(N^ε-decanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:159);
 (Aib⁸, Lys²⁶(N^ε-octanoyl), Arg³⁴, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:160);
 (Aib⁸, Lys²⁶(N^ε-tetradecanoyl), Arg³⁴, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:161);
 15 (Aib⁸, Lys²⁶(N^ε-hexadecanoyl), Arg³⁴, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:162);
 (Aib⁸, Lys²⁶(N^ε-decanoyl), Arg³⁴, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:163);
 (Aib^{8,35}, Lys³⁴(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:164);
 (Aib^{8,35}, Lys³⁴(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:165);
 (Aib^{8,35}, Lys³⁴(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:166);
 20 (Aib^{8,35}, Arg²⁶, Lys³⁴(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:167);
 (Aib^{8,35}, Arg²⁶, Lys³⁴(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:168);
 (Aib^{8,35}, Arg²⁶, Lys³⁴(N^ε-decanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:169);
 (Aib^{8,35}, Arg^{25,26}, Lys³⁴(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:170);
 (Aib^{8,35}, Arg^{25,26}, Lys³⁴(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:171);
 25 (Aib^{8,35}, Arg^{25,26}, Lys³⁴(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:172);
 (Aib^{8,35}, Arg^{25,26}, Lys³⁴(N^ε-decanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:173);
 (Aib^{8,35}, Lys²⁵, Arg²⁶, Lys³⁴(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:174);
 (Aib^{8,35}, Lys²⁵, Arg²⁶, Lys³⁴(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:175);
 (Aib^{8,35}, Lys²⁵, Arg²⁶, Lys³⁴(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:176);
 30 (Aib^{8,35}, Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:177);
 (Aib^{8,35}, Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:178);

- (Aib^{8,35}, Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:179);
 (Aib^{8,35}, Arg²⁶, Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:180);
 (Aib^{8,35}, Arg²⁶, Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:181);
 (Aib^{8,35}, Arg²⁶, Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:182);
 5 (Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:183);
 (Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:184);
 (Aib^{8,35}, Arg^{26,34}, Lys³⁸(N^ε-octanoyl))hGLP-1(7-38)NH₂ (SEQ ID NO:185);
 (Aib^{8,35}, Arg^{26,34}, Lys³⁸(N^ε-decanoyl))hGLP-1(7-38)NH₂ (SEQ ID NO:186);
 (Aib^{8,35}, Arg^{26,34}, Lys³⁸(N^ε-tetradecanoyl))hGLP-1(7-38)NH₂ (SEQ ID NO:187);
 10 (Aib^{8,35}, Arg^{26,34}, Lys³⁸(N^ε-hexadecanoyl))hGLP-1(7-38)NH₂ (SEQ ID NO:188);
 (Aib^{8,35,37}, Arg^{25,26,34}, Lys³⁸(N^ε-octanoyl))hGLP-1(7-38)NH₂ (SEQ ID NO:189);
 (Aib^{8,35,37}, Arg^{25,26,34}, Lys³⁸(N^ε-decanoyl))hGLP-1(7-38)NH₂ (SEQ ID NO:190);
 (Aib^{8,35,37}, Arg^{25,26,34}, Lys³⁸(N^ε-tetradecanoyl))hGLP-1(7-38)NH₂ (SEQ ID NO:191);
 (Aib^{8,35,37}, Arg^{25,26,34}, Lys³⁸(N^ε-hexadecanoyl))hGLP-1(7-38)NH₂ (SEQ ID NO:192);
 15 (Aib^{8,35,37}, Arg^{26,34}, Lys³⁸(N^ε-octanoyl))hGLP-1(7-38)NH₂ (SEQ ID NO:193);
 (Aib^{8,35,37}, Arg^{26,34}, Lys³⁸(N^ε-decanoyl))hGLP-1(7-38)NH₂ (SEQ ID NO:194);
 (Aib^{8,35,37}, Arg^{26,34}, Lys³⁸(N^ε-hexadecanoyl))hGLP-1(7-38)NH₂ (SEQ ID NO:195);
 (Aib^{8,35,37}, Arg^{25,26,34}, Lys³⁸(N^ε-octanoyl))hGLP-1(7-38)NH₂ (SEQ ID NO:189);
 (Aib^{8,35,37}, Arg^{25,26,34}, Lys³⁸(N^ε-decanoyl))hGLP-1(7-38)NH₂ (SEQ ID NO:190);
 20 (Aib^{8,35,37}, Arg^{25,26,34}, Lys³⁸(N^ε-tetradecanoyl))hGLP-1(7-38)NH₂ (SEQ ID NO:191);
 (Aib^{8,35,37}, Arg^{25,26,34}, Lys³⁸(N^ε-hexadecanoyl))hGLP-1(7-38)NH₂ (SEQ ID NO:192);
 (Aib^{8,35}, Lys²⁵, Arg^{26,34}, Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:196);
 (Aib^{8,35}, Lys²⁵, Arg^{26,34}, Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:197);
 (Aib^{8,35}, Lys²⁵, Arg^{26,34}, Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:198);
 25 (Aib^{8,35}, Arg^{25,26,34}, Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:199);
 (Aib^{8,35}, Arg^{25,26,34}, Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:200);
 (Aib^{8,35}, Arg^{25,26,34}, Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:201);
 (Aib^{8,35}, Arg^{25,26,34}, Lys³⁶(N^ε-decanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:202);
 (Aib⁸, Lys³⁴(N^ε-octanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:203);
 30 (Aib⁸, Lys³⁴(N^ε-tetradecanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:204);
 (Aib⁸, Lys³⁴(N^ε-hexadecanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:205);

- (Aib⁸, A6c³², Lys³⁴(N^ε-octanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:206);
 (Aib⁸, Glu²³, Lys³⁴(N^ε-octanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:207);
 (Aib⁸, Glu²³, A6c³², Lys³⁴(N^ε-octanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:208);
 (Aib⁸, Arg²⁶, Lys³⁴(N^ε-octanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:209);
 5 (Aib⁸, Arg²⁶, Lys³⁴(N^ε-tetradecanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:210);
 (Aib⁸, Arg²⁶, Lys³⁴(N^ε-hexadecanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:211);
 (Aib⁸, Arg²⁶, Lys³⁴(N^ε-decanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:212);
 (Aib⁸, Arg^{25,26}, Lys³⁴(N^ε-octanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:213);
 (Aib⁸, Arg^{25,26}, Lys³⁴(N^ε-tetradecanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:214);
 10 (Aib⁸, Arg^{25,26}, Lys³⁴(N^ε-hexadecanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:215);
 (Aib⁸, Arg^{25,26}, Lys³⁴(N^ε-decanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:216);
 (Aib⁸, Lys²⁵, Arg²⁶, Lys³⁴(N^ε-octanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:217);
 (Aib⁸, Lys²⁵, Arg²⁶, Lys³⁴(N^ε-tetradecanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:218);
 (Aib⁸, Lys²⁵, Arg²⁶, Lys³⁴(N^ε-hexadecanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:219);
 15 (Aib⁸, β-Ala³⁵, Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:220);
 (Aib⁸, β-Ala³⁵, Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:221);
 (Aib⁸, β-Ala³⁵, Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:222);
 (Aib⁸, Arg²⁶, β-Ala³⁵, Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:223);
 (Aib⁸, Arg²⁶, β-Ala³⁵, Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:224);
 20 (Aib⁸, Arg²⁶, β-Ala³⁵, Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:225);
 (Aib⁸, Arg^{26,34}, β-Ala³⁵, Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:226);
 (Aib⁸, Arg^{26,34}, β-Ala³⁵, Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:227);
 (Aib⁸, Arg^{26,34}, β-Ala³⁵, Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:228);
 (Aib⁸, Arg^{26,34}, β-Ala³⁵, Lys³⁶(N^ε-decanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:229);
 25 (Aib⁸, Lys²⁵, Arg^{26,34}, β-Ala³⁵, Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:230);
 (Aib⁸, Lys²⁵, Arg^{26,34}, Lys³⁶(N^ε-tetradecanoyl), β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:231);
 (Aib⁸, Lys²⁵, Arg^{26,34}, β-Ala³⁵, Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:232);
 (Aib⁸, Arg^{25,26,34}, β-Ala³⁵, Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:233);
 (Aib⁸, Arg^{25,26,34}, β-Ala³⁵, Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:234);
 30 (Aib⁸, Arg^{25,26,34}, β-Ala³⁵, Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:235);
 (Aib⁸, Arg^{25,26,34}, β-Ala³⁵, Lys³⁶(N^ε-decanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:236);

- (Aib^{8,35}, Lys²⁶(N^ε-octanoyl), A6c³², Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:237);
 (Aib^{8,35}, Lys²⁶(N^ε-tetradecanoyl), A6c³², Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:238);
 (Aib^{8,35}, Lys²⁶(N^ε-hexadecanoyl), A6c³², Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:239);
 (Aib^{8,35}, A6c³², Lys³⁴(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:240);
 5 (Aib^{8,35}, A6c³², Lys³⁴(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:241);
 (Aib^{8,35}, A6c³², Lys³⁴(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:242);
 (Aib^{8,35}, Arg²⁶, A6c³², Lys³⁴(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:243);
 (Aib^{8,35}, Arg²⁶, A6c³², Lys³⁴(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:244);
 (Aib^{8,35}, A6c³², Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:245);
 10 (Aib^{8,35}, A6c³², Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:246);
 (Aib^{8,35}, A6c³², Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:247);
 (Aib^{8,35}, Arg²⁶, A6c³², Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:248);
 (Aib^{8,35}, Arg²⁶, A6c³², Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:249);
 (Aib^{8,35}, Arg²⁶, A6c³², Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:250);
 15 (Aib^{8,35}, Arg^{26,34}, A6c³², Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:251);
 (Aib^{8,35}, Arg^{26,34}, A6c³², Lys³⁶(N^ε-decanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:252);
 (Aib^{8,35}, Arg^{26,34}, A6c³², Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:253);
 (Aib^{8,35}, Arg^{26,34}, A6c³², Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:254);
 (Aib^{8,24,35}, Lys²⁶(N^ε-octanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:255);
 20 (Aib^{8,24,35}, Lys²⁶(N^ε-tetradecanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:256);
 (Aib^{8,24,35}, Lys²⁶(N^ε-hexadecanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:257);
 (Aib^{8,24,35}, Arg²⁶, Lys³⁴(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:258);
 (Aib^{8,24,35}, Arg²⁶, Lys³⁴(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:259);
 (Aib^{8,24,35}, Arg²⁶, Lys³⁴(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:260);
 25 (Aib^{8,24,35}, Arg^{26,34}, Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:261);
 (Aib^{8,24,35}, Arg^{26,34}, Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:262);
 (Aib^{8,24,35}, Arg^{26,34}, Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:263);
 (Aib^{8,24,35}, Glu²³, A6c³², Lys³⁴(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:264);
 (Aib^{8,35}, Glu²³, Lys²⁶(N^ε-octanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:265);
 30 (Aib^{8,35}, Glu²³, Lys²⁶(N^ε-tetradecanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:266);
 (Aib^{8,35}, Glu²³, Lys²⁶(N^ε-hexadecanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:267);

- (Aib^{8,35}, Glu²³, Lys³⁴(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:268);
 (Aib^{8,35}, Glu²³, A6c³², Lys³⁴(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:269);
 (Aib^{8,35}, Glu²³, Arg²⁶, Lys³⁴(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:270);
 (Aib^{8,35}, Glu²³, Arg²⁶, Lys³⁴(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:271);
 5 (Aib^{8,35}, Glu²³, Arg²⁶, Lys³⁴(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:272);
 (Aib^{8,35}, Glu²³, Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:273);
 (Aib^{8,35}, Glu²³, Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:274);
 (Aib^{8,35}, Glu²³, Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:275);
 (Aib^{8,35}, Glu²³, Arg^{26,34}, Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:276);
 10 (Aib^{8,35}, Glu²³, Arg^{26,34}, Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:277);
 (Aib^{8,35}, Glu²³, Arg^{26,34}, Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:278);
 (Aib^{8,30,35}, Lys²⁶(N^ε-octanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:279);
 (Aib^{8,30,35}, Lys²⁶(N^ε-tetradecanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:280);
 (Aib^{8,30,35}, Lys²⁶(N^ε-hexadecanoyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:281);
 15 (Aib^{8,30,35}, Arg²⁶, Lys³⁴(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:282);
 (Aib^{8,30,35}, Arg²⁶, Lys³⁴(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:283);
 (Aib^{8,30,35}, Arg²⁶, Lys³⁴(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:284);
 (Aib^{8,30,35}, Arg^{26,34}, Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:285);
 (Aib^{8,30,35}, Arg^{26,34}, Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:286);
 20 (Aib^{8,30,35}, Arg^{26,34}, Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:287);
 (Aib^{8,35}, Glu²³, A6c³², Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:288);
 (Aib^{8,35}, Glu²³, A6c³², Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:289);
 (Aib^{8,35}, Glu²³, A6c³², Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:290);
 (Aib^{8,35}, Glu²³, Arg^{26,34}, A6c³², Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:291);
 25 (Aib^{8,35}, Glu²³, Arg^{26,34}, A6c³², Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:292);
 (Aib^{8,35}, Glu²³, Arg^{26,34}, A6c³², Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:293);
 (Aib^{8,24,35}, Glu²³, Arg^{26,34}, A6c³², Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:294);
 (Aib^{8,24,35}, Glu²³, Arg^{26,34}, A6c³², Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:295);
 (Aib^{8,24,35}, Glu²³, Arg^{26,34}, A6c³², Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:296);
 30 (Aib^{8,24,30,35}, Glu²³, Arg^{26,34}, A6c³², Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:297);

- (Aib^{8,24,30,35}, Glu²³, Arg^{26,34}, A6c³², Lys³⁶(N^ε-tetradecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:298);
- (Aib^{8,24,30,35}, Glu²³, Arg^{26,34}, A6c³², Lys³⁶(N^ε-hexadecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:299);
- 5 ((N^α-HEPES-His)⁷, Aib³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:300);
- ((N^α-HEPES-His)⁷, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:301);
- ((N^α-HEPES-His)⁷, Aib⁸, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:302);
- ((N^α-HEPA-His)⁷, Aib³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:303);
- ((N^α-HEPA-His)⁷, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:304);
- 10 ((N^α-HEPA-His)⁷, Aib⁸, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:305);
- ((N^α-tetradecanoyl-His)⁷, Aib³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:306);
- ((N^α-tetradecanoyl-His)⁷, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:307);
- ((N^α-tetradecanoyl-His)⁷, Aib^{8,35})hGLP-1(7-36)NH₂ (SEQ ID NO:308);
- ((N^α-tetradecanoyl-His)⁷, Aib⁸, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:309);
- 15 ((N^α-tetradecanoyl-His)⁷, Arg^{26,34}, Aib³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:310);
- ((N^α-tetradecanoyl-His)⁷, Arg^{26,34}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:311);
- ((N^α-tetradecanoyl-His)⁷, Aib^{8,35}, Arg^{26,34})hGLP-1(7-36)NH₂ (SEQ ID NO:312);
- ((N^α-tetradecanoyl-His)⁷, Aib⁸, Arg^{26,34}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:313);
- ((N^α-tetradecanoyl-His)⁷, Arg^{25,26,34}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:314);
- 20 ((N^α-tetradecanoyl-His)⁷, Aib^{8,35}, Arg^{25,26,34})hGLP-1(7-36)NH₂ (SEQ ID NO:315);
- ((N^α-tetradecanoyl-His)⁷, Aib⁸, Arg^{25,26,34}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:316);
- (Aib^{8,35}, Lys²⁶(N^ε-octanesulfonyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:317);
- (Aib^{8,35}, Lys²⁶(N^ε-dodecanesulfonyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:318);
- (Aib^{8,35}, Lys²⁶(N^ε-hexadecanesulfonyl), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:319);
- 25 (Aib^{8,35}, Arg²⁶, Lys³⁴(N^ε-octanesulfonyl))hGLP-1(7-36)NH₂ (SEQ ID NO:320);
- (Aib^{8,35}, Arg²⁶, Lys³⁴(N^ε-dodecanesulfonyl))hGLP-1(7-36)NH₂ (SEQ ID NO:321);
- (Aib^{8,35}, Arg²⁶, Lys³⁴(N^ε-hexadecanesulfonyl))hGLP-1(7-36)NH₂ (SEQ ID NO:322);
- (Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^ε-octanesulfonyl))hGLP-1(7-36)NH₂ (SEQ ID NO:323);
- (Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^ε-hexadecanesulfonyl))hGLP-1(7-36)NH₂ (SEQ ID NO:324);
- 30 (Aib^{8,35}, Asp²⁶(1-(4-decylpiperazine)), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:325);
- (Aib^{8,35}, Asp²⁶(1-(4-dodecylpiperazine)), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:326);

- (Aib^{8,35}, Asp²⁶(1-(4-tetradecylpiperazine)), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:327);
 (Aib^{8,35}, Asp²⁶(1-(4-hexadecylpiperazine)), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:328);
 (Aib^{8,35}, Arg²⁶, Asp³⁴(1-(4-decylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:329);
 (Aib^{8,35}, Arg²⁶, Asp³⁴(1-(4-dodecylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:330);
 5 (Aib^{8,35}, Arg²⁶, Asp³⁴(1-(4-tetradecylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:331);
 (Aib^{8,35}, Arg²⁶, Asp³⁴(1-(4-hexadecylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:332);
 (Aib^{8,35}, Arg^{26,34}, Asp³⁶(1-(4-decylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:333);
 (Aib^{8,35}, Arg^{26,34}, Asp³⁶(1-(4-dodecylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:334);
 (Aib^{8,35}, Arg^{26,34}, Asp³⁶(1-(4-hexadecylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:335);
 10 (Aib^{8,35}, Arg^{26,34}, Asp³⁸(1-(4-decylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:336);
 (Aib^{8,35}, Arg^{26,34}, Asp³⁸(1-(4-dodecylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:337);
 (Aib^{8,35}, Arg^{26,34}, Asp³⁸(1-(4-tetradecylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:338);
 (Aib^{8,35}, Arg^{26,34}, Asp³⁸(1-(4-hexadecylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:339);
 (Aib^{8,35,37}, Arg^{26,34}, Asp³⁸(1-(4-decylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:340);
 15 (Aib^{8,35,37}, Arg^{26,34}, Asp³⁸(1-(4-dodecylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:341);
 (Aib^{8,35,37}, Arg^{26,34}, Asp³⁸(1-(4-tetradecylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:342);
 (Aib^{8,35,37}, Arg^{26,34}, Asp³⁸(1-(4-hexadecylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:343);
 (Aib^{8,35}, Arg^{25,34}, Asp²⁶(1-(4-decylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:344);
 (Aib^{8,35}, Arg^{25,34}, Asp²⁶(1-(4-dodecylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:345);
 20 (Aib^{8,35}, Arg^{25,34}, Asp²⁶(1-(4-tetradecylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:346);
 (Aib^{8,35}, Arg^{25,34}, Asp²⁶(1-(4-hexadecylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:347);
 (Aib^{8,35}, Arg^{25,26}, Asp³⁴(1-(4-decylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:348);
 (Aib^{8,35}, Arg^{25,26}, Asp³⁴(1-(4-dodecylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:349);
 (Aib^{8,35}, Arg^{25,26}, Asp³⁴(1-(4-tetradecylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:350);
 25 (Aib^{8,35}, Arg^{25,26}, Asp³⁴(1-(4-hexadecylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:351);
 (Aib^{8,35}, Arg^{25,26,34}, Asp³⁶(1-(4-decylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:352);
 (Aib^{8,35}, Arg^{25,26,34}, Asp³⁶(1-(4-dodecylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:353);
 (Aib^{8,35}, Arg^{25,26,34}, Asp³⁶(1-(4-tetradecylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:354);
 (Aib^{8,35}, Arg^{25,26,34}, Asp³⁶(1-(4-hexadecylpiperazine)))hGLP-1(7-36)NH₂ (SEQ ID NO:355);
 30 (Aib^{8,35}, Arg^{25,26,34}, Asp³⁸(1-(4-decylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:356);
 (Aib^{8,35}, Arg^{25,26,34}, Asp³⁸(1-(4-dodecylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:357);

- (Aib^{8,35}, Arg^{25,26,34}, Asp³⁸(1-(4-tetradecylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:358);
 (Aib^{8,35}, Arg^{25,26,34}, Asp³⁸(1-(4-hexadecylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:359);
 (Aib^{8,35,37}, Arg^{25,26,34}, Asp³⁸(1-(4-decylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:360);
 (Aib^{8,35,37}, Arg^{25,26,34}, Asp³⁸(1-(4-dodecylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:361);
 5 (Aib^{8,35,37}, Arg^{25,26,34}, Asp³⁸(1-(4-tetradecylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:362);
 (Aib^{8,35,37}, Arg^{25,26,34}, Asp³⁸(1-(4-hexadecylpiperazine)))hGLP-1(7-38)NH₂ (SEQ ID NO:363);
 (Aib^{8,35}, Arg^{26,34}, Glu³⁶(1-dodecylamino))hGLP-1(7-36)NH₂ (SEQ ID NO:364);
 (Aib^{8,35}, Glu²⁶(1-dodecylamino), Arg³⁴)hGLP-1(7-36)NH₂ (SEQ ID NO:365);
 (Aib^{8,35}, Arg²⁶, Glu³⁴(1-dodecylamino))hGLP-1(7-36)NH₂ (SEQ ID NO:366);
 10 (Aib^{8,35,37}, Arg^{26,34}, Glu³⁸(1-dodecylamino))hGLP-1(7-38)NH₂ (SEQ ID NO:367);
 (Aib^{8,35}, Arg³⁴, Lys²⁶(N^ε-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:368);
 (Aib^{8,35}, Arg³⁴, Lys²⁶(N^ε-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:369);
 15 (Aib^{8,35}, Arg³⁴, Lys²⁶(N^ε-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:370);
 (Aib^{8,35}, Arg³⁴, Lys²⁶(N^ε-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:371);
 (Aib^{8,35}, Arg²⁶, Lys³⁴(N^ε-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:372);
 20 (Aib^{8,35}, Arg²⁶, Lys³⁴(N^ε-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:373);
 (Aib^{8,35}, Arg²⁶, Lys³⁴(N^ε-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:374);
 25 (Aib^{8,35}, Arg²⁶, Lys³⁴(N^ε-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:375);
 (Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^ε-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:376);
 (Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^ε-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:377);
 30

- (Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^ε-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:378);
- (Aib^{8,35}, Arg^{26,34}, Lys³⁸(N^ε-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH₂ (SEQ ID NO:379);
- 5 (Aib^{8,35}, Arg^{26,34}, Lys³⁸(N^ε-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH₂ (SEQ ID NO:380);
- (Aib^{8,35}, Arg^{26,34}, Lys³⁸(N^ε-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH₂ (SEQ ID NO:381);
- (Aib^{8,35}, Arg^{26,34}, Lys³⁸(N^ε-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH₂ (SEQ ID
- 10 NO:382);
- (Aib^{8,35,37}, Arg^{26,34}, Lys³⁸(N^ε-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH₂ (SEQ ID NO:383);
- (Aib^{8,35,37}, Arg^{26,34}, Lys³⁸(N^ε-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH₂ (SEQ ID NO:384);
- 15 (Aib^{8,35,37}, Arg^{26,34}, Lys³⁸(N^ε-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH₂ (SEQ ID NO:385);
- (Aib^{8,35,37}, Arg^{26,34}, Lys³⁸(N^ε-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH₂ (SEQ ID NO:386);
- (Aib^{8,35}, Arg^{25,34}, Lys²⁶(N^ε-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID
- 20 NO:387);
- (Aib^{8,35}, Arg^{25,34}, Lys²⁶(N^ε-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:388);
- (Aib^{8,35}, Arg^{25,34}, Lys²⁶(N^ε-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:389);
- 25 (Aib^{8,35}, Arg^{25,34}, Lys²⁶(N^ε-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:390);
- (Aib^{8,35}, Arg^{25,26}, Lys³⁴(N^ε-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:391);
- (Aib^{8,35}, Arg^{25,26}, Lys³⁴(N^ε-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID
- 30 NO:392);

- (Aib^{8,35}, Arg^{25,26}, Lys³⁴(N^ε-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:393);
- (Aib^{8,35}, Arg^{25,26}, Lys³⁴(N^ε-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:394);
- 5 (Aib^{8,35}, Arg^{25,26,34}, Lys³⁶(N^ε-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:395);
- (Aib^{8,35}, Arg^{25,26,34}, Lys³⁶(N^ε-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:396);
- (Aib^{8,35}, Arg^{25,26,34}, Lys³⁶(N^ε-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID
- 10 NO:397);
- (Aib^{8,35}, Arg^{25,26,34}, Lys³⁶(N^ε-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH₂ (SEQ ID NO:398);
- (Aib^{8,35}, Arg^{25,26,34}, Lys³⁸(N^ε-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH₂ (SEQ ID NO:399);
- 15 (Aib^{8,35}, Arg^{25,26,34}, Lys³⁸(N^ε-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH₂ (SEQ ID NO:400);
- (Aib^{8,35}, Arg^{25,26,34}, Lys³⁸(N^ε-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH₂ (SEQ ID NO:401);
- (Aib^{8,35}, Arg^{25,26,34}, Lys³⁸(N^ε-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH₂ (SEQ ID
- 20 NO:402);
- (Aib^{8,35,37}, Arg^{25,26,34}, Lys³⁸(N^ε-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH₂ (SEQ ID NO:403);
- (Aib^{8,35,37}, Arg^{25,26,34}, Lys³⁸(N^ε-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH₂ (SEQ ID NO:404);
- 25 (Aib^{8,35,37}, Arg^{25,26,34}, Lys³⁸(N^ε-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH₂ (SEQ ID NO:405);
- (Aib^{8,35,37}, Arg^{25,26,34}, Lys³⁸(N^ε-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH₂ (SEQ ID NO:406);
- (Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^ε-decanoyl))hGLP-1(7-36)OH (SEQ ID NO:407);
- 30 (Aib^{8,35}, Lys²⁵, Arg^{26,34}, Lys³⁶(N^ε-decanoyl))hGLP-1(7-36)OH (SEQ ID NO:408);
- (Aib^{8,35}, Arg^{26,34}, Ava³⁷, Ado³⁸)hGLP-1(7-38)NH₂ (SEQ ID NO:409);

- (Aib^{8,35}, Arg^{26,34}, Asp³⁷, Ava³⁸, Ado³⁹)hGLP-1(7-39)NH₂ (SEQ ID NO:27);
 (Aib^{8,35}, Arg^{26,34}, Aun³⁷)hGLP-1(7-37)NH₂ (SEQ ID NO:28);
 (Aib^{8,17,35})hGLP-1(7-36)NH₂ (SEQ ID NO:29);
 (Aib⁸, Arg^{26,34}, β-Ala³⁵, D-Asp³⁷, Ava³⁸, Aun³⁹)hGLP-1(7-39)NH₂ (SEQ ID NO:30);
 5 (Gly⁸, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:31);
 (Ser⁸, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:32);
 (Aib⁸, Glu^{22,23}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:33);
 (Gly⁸, Aib³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:34);
 (Aib⁸, Lys¹⁸, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:35);
 10 (Aib⁸, Leu²⁷, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:36);
 (Aib⁸, Lys³³, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:37);
 (Aib⁸, Lys¹⁸, Leu²⁷, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:38);
 (Aib⁸, D-Arg³⁶)hGLP-1(7-36)NH₂ (SEQ ID NO:39);
 (Aib⁸, β-Ala³⁵, D-Arg³⁷)hGLP-1(7-37)NH₂ (SEQ ID NO:40);
 15 (Aib^{8,27}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:41);
 (Aib^{8,27}, β-Ala^{35,37}, Arg³⁸)hGLP-1(7-38)NH₂ (SEQ ID NO:42);
 (Aib^{8,27}, β-Ala^{35,37}, Arg^{38,39})hGLP-1(7-39)NH₂ (SEQ ID NO:43);
 (Aib⁸, Lys^{18,27}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:44);
 (Aib⁸, Lys²⁷, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:45);
 20 (Aib⁸, β-Ala³⁵, Arg³⁸)hGLP-1(7-38)NH₂ (SEQ ID NO:46);
 (Aib⁸, Arg^{26,34}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:47);
 (Aib⁸, D-Arg³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:48);
 (Aib⁸, β-Ala³⁵, Arg³⁷)hGLP-1(7-37)NH₂ (SEQ ID NO:49);
 (Aib⁸, Phe³¹, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:50);
 25 (Aib^{8,35}, Phe³¹)hGLP-1(7-36)NH₂ (SEQ ID NO:51);
 (Aib^{8,35}, Nal³¹)hGLP-1(7-36)NH₂ (SEQ ID NO:52);
 (Aib^{8,35}, Nal^{28,31})hGLP-1(7-36)NH₂ (SEQ ID NO:53);
 (Aib^{8,35}, Arg^{26,34}, Nal³¹)hGLP-1(7-36)NH₂ (SEQ ID NO:54);
 (Aib^{8,35}, Arg^{26,34}, Phe³¹)hGLP-1(7-36)NH₂ (SEQ ID NO:55);
 30 (Aib^{8,35}, Nal^{19,31})hGLP-1(7-36)NH₂ (SEQ ID NO:56);
 (Aib^{8,35}, Nal^{12,31})hGLP-1(7-36)NH₂ (SEQ ID NO:57);

- (Aib^{8,35}, Lys³⁶(N^ε-decanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:58);
 (Aib^{8,35}, Arg³⁴, Lys²⁶(N^ε-decanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:59);
 (Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^ε-dodecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:60);
 (Aib⁸, β-Ala³⁵, Ser³⁷(O-decanoyl))hGLP-1(7-37)NH₂ (SEQ ID NO:61);
 5 (Aib^{8,27}, β-Ala^{35,37}, Arg³⁸, Lys³⁹(N^ε-octanoyl))hGLP-1(7-39)NH₂ (SEQ ID NO:62);
 (Aib⁸, Arg^{26,34}, β-Ala³⁵, Lys³⁷(N^ε-octanoyl))hGLP-1(7-37)NH₂ (SEQ ID NO:63);
 (Aib⁸, Arg^{26,34}, β-Ala³⁵, Lys³⁷(N^ε-decanoyl))hGLP-1(7-37)NH₂ (SEQ ID NO:64);
 (Aib⁸, Arg^{26,34}, β-Ala³⁵, Lys³⁷(N^ε-tetradecanoyl))hGLP-1(7-37)NH₂ (SEQ ID NO:65);
 (Aib⁸, Arg^{26,34}, β-Ala³⁵, Lys³⁷(N^ε-dodecanoyl))hGLP-1(7-37)NH₂ (SEQ ID NO:410); or
 10 (Aib⁸, Arg^{26,34}, β-Ala³⁵, Lys³⁷(N^ε-dodecanoyl))hGLP-1(8-37)NH₂ (SEQ ID NO:411);
 or a pharmaceutically acceptable salt thereof.

16. (Amended) A compound according to claim 15 wherein said compound is
 (Aib^{8,35}, A6c³²)hGLP-1(7-36)NH₂ (SEQ ID NO:16);
 15 (Aib^{8,35}, Glu²³)hGLP-1(7-36)NH₂ (SEQ ID NO:17);
 (Aib^{8,24,35})hGLP-1(7-36)NH₂ (SEQ ID NO:18);
 (Aib^{8,35}, Glu²³, A6c³²)hGLP-1(7-36)NH₂ (SEQ ID NO:19);
 (Aib⁸, Glu²³, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:20);
 (Aib^{8,35}, Arg^{26,34})hGLP-1(7-36)NH₂ (SEQ ID NO:21);
 20 (Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^ε-octanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:22);
 (Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^ε-decanoyl))hGLP-1(7-36)OH (SEQ ID NO:23);
 (Aib^{8,35}, Lys²⁵, Arg^{26,34}Lys³⁶(N^ε-decanoyl))hGLP-1(7-36)OH (SEQ ID NO:24);
 (Aib⁸, Arg^{26,34}, β-Ala³⁵, Lys³⁶(N^ε-Aec-decanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:25);
 (Aib^{8,35}, Arg^{26,34}, Ava³⁷, Ado³⁸)hGLP-1(7-38)NH₂ (SEQ ID NO:26);
 25 (Aib^{8,35}, Arg^{26,34}, Asp³⁷, Ava³⁸, Ado³⁹)hGLP-1(7-39)NH₂ (SEQ ID NO:27);
 (Aib^{8,35}, Arg^{26,34}, Aun³⁷)hGLP-1(7-37)NH₂ (SEQ ID NO:28);
 (Aib^{8,17,35})hGLP-1(7-36)NH₂ (SEQ ID NO:29);
 (Aib⁸, Arg^{26,34}, β-Ala³⁵, D-Asp³⁷, Ava³⁸, Aun³⁹)hGLP-1(7-39)NH₂ (SEQ ID NO:30);
 (Gly⁸, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:31);
 30 (Ser⁸, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:32);
 (Aib⁸, Glu^{22,23}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:33);

- (Gly⁸, Aib³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:34);
- (Aib⁸, Lys¹⁸, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO: 35);
- (Aib⁸, Leu²⁷, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:36);
- (Aib⁸, Lys³³, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:37);
- 5 (Aib⁸, Lys¹⁸, Leu²⁷, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:38);
- (Aib⁸, D-Arg³⁶)hGLP-1(7-36)NH₂ (SEQ ID NO:39);
- (Aib⁸, β-Ala³⁵, D-Arg³⁷)hGLP-1(7-37)NH₂ (SEQ ID NO:40);
- (Aib^{8,27}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:41);
- (Aib^{8,27}, β-Ala^{35,37}, Arg³⁸)hGLP-1(7-38)NH₂ (SEQ ID NO:42);
- 10 (Aib^{8,27}, β-Ala^{35,37}, Arg^{38,39})hGLP-1(7-39)NH₂ (SEQ ID NO:43);
- (Aib⁸, Lys^{18,27}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:44);
- (Aib⁸, Lys²⁷, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:45);
- (Aib⁸, β-Ala³⁵, Arg³⁸)hGLP-1(7-38)NH₂ (SEQ ID NO:46);
- (Aib⁸, Arg^{26,34}, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:47);
- 15 (Aib⁸, D-Arg³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:48);
- (Aib⁸, β-Ala³⁵, Arg³⁷)hGLP-1(7-37)NH₂ (SEQ ID NO:49);
- (Aib⁸, Phe³¹, β-Ala³⁵)hGLP-1(7-36)NH₂ (SEQ ID NO:50);
- (Aib^{8,35}, Phe³¹)hGLP-1(7-36)NH₂ (SEQ ID NO:51);
- (Aib^{8,35}, Nal³¹)hGLP-1(7-36)NH₂ (SEQ ID NO:52);
- 20 (Aib^{8,35}, Nal^{28,31})hGLP-1(7-36)NH₂ (SEQ ID NO:53);
- (Aib^{8,35}, Arg^{26,34}, Nal³¹)hGLP-1(7-36)NH₂ (SEQ ID NO:54);
- (Aib^{8,35}, Arg^{26,34}, Phe³¹)hGLP-1(7-36)NH₂ (SEQ ID NO:55);
- (Aib^{8,35}, Nal^{19,31})hGLP-1(7-36)NH₂ (SEQ ID NO:56);
- (Aib^{8,35}, Nal^{12,31})hGLP-1(7-36)NH₂ (SEQ ID NO:57);
- 25 (Aib^{8,35}, Lys³⁶(N^ε-decanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:58);
- (Aib^{8,35}, Arg³⁴, Lys²⁶(N^ε-decanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:59);
- (Aib^{8,35}, Arg^{26,34}, Lys³⁶(N^ε-dodecanoyl))hGLP-1(7-36)NH₂ (SEQ ID NO:60);
- (Aib⁸, β-Ala³⁵, Ser³⁷(O-decanoyl))hGLP-1(7-37)-NH₂ (SEQ ID NO:61);
- (Aib^{8,27}, β-Ala^{35,37}, Arg³⁸, Lys³⁹(N^ε-octanoyl))hGLP-1(7-39)NH₂ (SEQ ID NO:62);
- 30 (Aib⁸, Arg^{26,34}, β-Ala³⁵, Lys³⁷(N^ε-octanoyl))hGLP-1(7-37)NH₂ (SEQ ID NO:63);
- (Aib⁸, Arg^{26,34}, β-Ala³⁵, Lys³⁷(N^ε-decanoyl))hGLP-1(7-37)NH₂ (SEQ ID NO:64); or

(Aib⁸, Arg^{26,34}, β-Ala³⁵, Lys³⁷(N^ε-tetradecanoyl))hGLP-1(7-37)NH₂ (SEQ ID NO:65);
or a pharmaceutically acceptable salt thereof.

17. Use of a compound as claimed in any of claims 1, 9, or 15, in the preparation of a
5 medicament for the treatment of disease.

18. Use as claimed in claim 17, in which the disease is selected from the group consisting
of Type I diabetes, Type II diabetes, obesity, glucagonomas, secretory disorders of the airway,
metabolic disorder, arthritis, osteoporosis, central nervous system disease, restenosis and
10 neurodegenerative disease.